Literature for fenchylamine sulfonamide (XA22.001 inhibitor)

(Topics flags: I Inhibitor. To select only the references relevant to a single topic, click the link above. See explanation.)

2008
1. Carter,D.B., Dunn,E., Pauley,A.M., McKinley,D.D., Fleck,T.J., Ellerbrook,B.R., Stratman,N.C., Zhou,X., Himes,C.S., Nye,J.S., Tomasselli,A. and Yan,R.
   Changes in gamma-secretase activity and specificity caused by the introduction of consensus aspartyl protease active motif in presenilin 1
   Mol Neurodegener3, 6-6. PubMed  Europe PubMed DOI  I
2003
2. [YEAR:1-11-2003]Petit,A., Pasini,A., Alves da Costa,C., Ayral,E., Hernandez,J.F., Dumanchin-Njock,C., Phiel,C.J., Marambaud,P., Wilk,S., Farzan,M., Fulcrand,P., Martinez,J., Andrau,D. and Checler,F.
   JLK isocoumarin inhibitors: selective gamma-secretase inhibitors that do not interfere with notch pathway in vitro or in vivo
   J Neurosci Res74, 370-377. PubMed  Europe PubMed DOI  I
2000
3. [YEAR:15-6-2000]Rishton,G.M., Retz,D.M., Tempest,P.A., Novotny,J., Kahn,S., Treanor,J.J., Lile,J.D. and Citron,M.
   Fenchylamine sulfonamide inhibitors of amyloid beta peptide production by the gamma-secretase proteolytic pathway: potential small-molecule therapeutic agents for the treatment of Alzheimer's disease
   J Med Chem43, 2297-2299. PubMed  Europe PubMed DOI  I